Texas to receive $286mn as Purdue Pharma's $7.4bn opioid settlement takes effect
The $7.4bn settlement between OxyContin manufacturer Purdue Pharma, its Sackler family owners and US states has taken legal effect, marking a long-awaited resolution to one of the most consequential corporate liability cases in modern American history and clearing the way for the disbursement of recovery funds to communities ravaged by the opioid crisis.
Ken Paxton, the Texas attorney-general, announced on Monday that the state would receive approximately $286.5mn under the agreement, lifting Texas's total recoveries from opioid-related settlements to more than $3bn. The bulk of the Purdue funds will be disbursed over the next three years, with payments continuing over a 15-year horizon.
Under the terms of the deal, members of the Sackler family — who built one of the most prominent dynasties of pharmaceutical wealth on the back of OxyContin's commercial success in the late 1990s and 2000s — are permanently barred from selling opioids in the United States. Purdue's operating businesses have been transferred to a new entity, Knoa Pharma LLC, which will be governed by an independent board and prohibited from marketing opioid products. An independent monitor has been appointed to help prevent the diversion of prescription opioids, and the agreement requires the public release of more than 30 million internal company documents — a disclosure obligation that is likely to provide material new evidence on corporate decision-making within Purdue during the years in which prescription opioid use proliferated across the country.
The settlement closes a chapter that began with Purdue's 2019 bankruptcy filing, prompted by a wave of lawsuits brought by states and territories alleging that the company had aggressively marketed OxyContin while downplaying its addictive potential. Texas filed suit in 2018 on broadly similar grounds. An earlier proposed resolution, reached in late 2023, was struck down by the US Supreme Court in 2024 over the controversial inclusion of broad civil liability shields for the Sackler family — a ruling that ultimately required the parties to renegotiate the deal on terms that more directly held the Sacklers financially accountable.
For Texas, where opioid-related overdoses have claimed thousands of lives over the past decade, the settlement funds are earmarked for addiction treatment, prevention programmes and recovery services. The crisis has shifted in recent years from one driven primarily by prescription painkillers to one increasingly dominated by illicit fentanyl, the synthetic opioid responsible for the bulk of US overdose deaths.
"For years, I have fought to ensure Big Pharma pays for its role in causing the opioid crisis, and this settlement is an important step in securing justice for victims," Paxton said in a statement.
The Purdue resolution is the largest in a sprawling matrix of opioid settlements that have together extracted tens of billions of dollars from drugmakers, distributors and pharmacy chains, including agreements with Johnson & Johnson, AmerisourceBergen, Cardinal Health, McKesson, Walmart, CVS and Walgreens. Yet the financial scale of the cumulative recoveries — significant though it is — is widely viewed as a partial accounting at best for the human and economic toll of an epidemic that has killed more than half a million Americans since the late 1990s.
The transition of Purdue's operations to Knoa Pharma marks one of the more unusual corporate restructurings in pharmaceutical history. The new entity will continue to manufacture certain Purdue products but will be required to operate under conditions that effectively reset the commercial culture that critics argued lay at the heart of OxyContin's spread. Whether the structural reforms succeed in preventing similar conduct elsewhere in the industry will depend in part on the rigour of the independent monitoring regime and on the regulatory and prescriber-level lessons drawn from the millions of documents now bound for public release.